341291 Sigma-AldrichFas/FasL Antagonist, Kp7-6 - Calbiochem
The Fas/FasL Antagonist, Kp7-6 controls the biological activity of Fas/FasL. This small molecule/inhibitor is primarily used for Cancer applications.
More>> The Fas/FasL Antagonist, Kp7-6 controls the biological activity of Fas/FasL. This small molecule/inhibitor is primarily used for Cancer applications. Less<<Synonyms: H-YC*DEHFC*Y-OH, Cyclic [Cys-Cys disulfide], Kp7-6
Recommended Products
Overview
Replacement Information |
---|
Key Spec Table
Empirical Formula |
---|
C₄₈H₅₆N₁₀O₁₅S₂ |
Pricing & Availability
Catalogue Number | Availability | Packaging | Qty/Pack | Price | Quantity | |
---|---|---|---|---|---|---|
341291-25MG |
|
Plastic ampoule | 25 mg |
|
— |
Description | |
---|---|
Overview | An exocyclic cystine-knot peptide that specifically antagonizes Fas/FasL-mediated cellular apoptotic signals (58% reduction of FasL-induced apoptosis in Jurkat cells at 1 mg/ml). Binds to FasL (Cat. Nos. PF033 and PF092) and Fas (CD95/APO-1) with comparable affinity (Kd = 11.2 & 13.2 µM, respectively), resulting in disabled receptor ensembles and altered signaling pathways. Shown to prevent Con A (Cat. No. 234567)-induced liver injury in a murine hepatitis model in vivo. Does not bind to TNF-α or TNFR. |
Catalogue Number | 341291 |
Brand Family | Calbiochem® |
Synonyms | H-YC*DEHFC*Y-OH, Cyclic [Cys-Cys disulfide], Kp7-6 |
References | |
---|---|
References | Carmona, E.M., et al. 2006. J. Immunol. 177, 459. Hasegawa, A., et al. 2004. Proc. Natl. Acad. Sci. USA 101, 6599. |
Product Information | |
---|---|
ATP Competitive | N |
Declaration | Sold under license of U.S. Patent 7,288,519. |
Form | White lyophilized powder |
Formulation | Supplied as a trifluoroacetate salt. |
Hill Formula | C₄₈H₅₆N₁₀O₁₅S₂ |
Chemical formula | C₄₈H₅₆N₁₀O₁₅S₂ |
Hygroscopic | Hygroscopic |
Reversible | N |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | Fas/FasL-mediated cellular apoptotic signals |
Primary Target IC<sub>50</sub> | Kd = 11.2 & 13.2 µM for FasL and Fas (CD95/APO-1), respectively |
Purity | ≥98% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | N |
Peptide Sequence | H₂N-Tyr-Cys*-Asp-Glu-His-Phe-Cys*-Tyr-CO₂H, Cyclic [disulfide bond between Cys-Cys] |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Catalogue Number | GTIN |
341291-25MG | 04055977215618 |
Documentation
Fas/FasL Antagonist, Kp7-6 - Calbiochem MSDS
Title |
---|
Fas/FasL Antagonist, Kp7-6 - Calbiochem Certificates of Analysis
Title | Lot Number |
---|---|
341291 |
References
Reference overview |
---|
Carmona, E.M., et al. 2006. J. Immunol. 177, 459. Hasegawa, A., et al. 2004. Proc. Natl. Acad. Sci. USA 101, 6599. |